Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab prophylaxis for neovascular AMD conversion
NCT02302989Phase 2Completed
- Start
- May 2015
- Primary completion
- Jul 2018
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in age-related macular degeneration (AMD). Started May 2015; status: completed.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT02302989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02302989.